🔴 BioXcel Therapeutics is trading 5.6% down today after $1.25 million financing, $250,000 fee

BioXcel Therapeutics is trading 5.6% down at $0.72 after announcing a fourteenth credit-agreement amendment on August 24, 2026.

• The company secured $1.25 million in additional term loans and paid a $250,000 upfront fee.
• Its minimum liquidity covenant fell to $250,000, while an August 31 capital-solution or repayment deadline remains, highlighting acute financing pressure despite broader biotech strength.